暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股市场个股详情
ICCM Icecure Medical
- 1.200
- +0.010+0.84%
收盘价 04/26 16:00 (美东)
- 1.200
- 0.000-0.02%
盘后 18:25 (美东)
5487.56万总市值-3750市盈率TTM
1.218最高价1.180最低价6.06万股成交量1.210今开1.190昨收7.23万成交额0.32%换手率亏损市盈率(静)4572.97万总股本1.57052周最高4.51市净率2268.41万流通值0.52052周最低--股息TTM1890.34万流通股16.000历史最高--股息率TTM3.21%振幅0.520历史最低1.193平均价1股每手
全部分时
- 5日
- 日K
- 周K
- 月K
- 季K
- 年K
资金分布
单位: --
资金流向
实时日周月
暂无数据
新闻
分析师对医疗保健公司发表见解：Icecure Medical（ICCM）、Viracta Therapeutics（VIRX）和Bioxcel Therapeutics（BTAI）
IceCure Medical宣布即将举行的股东大会
IceCure Medical 获得 FDA 批准，试验结果令人鼓舞
IceCure Medical 寻求 FDA 批准 ProSense 治疗早期乳腺癌
IceCure Medical（ICCM）表示，它已向美国食品药品监督管理局提交了最终数据，寻求ProSense的上市许可，用于治疗早期T1浸润性乳腺癌患者
快讯 | Icecure 医疗报告最终的 Ice3 乳腺癌冷冻消融试验结果为患者和医生满意度为 100%，无复发率为 96.3%：提交给美国食品药品管理局申请上市许可以治疗早期乳腺癌的数据
IceCure医疗报告ICE3乳腺癌冷冻消融试验的最终结果为患者和医生满意度为100％，无复发率为96.3％：已提交给美国食品药品管理局申请上市许可以治疗早期乳腺癌的数据
理查德·芬博士在极具影响力的美国乳腺外科学会（“ASBR”）年会上发表的数据获得了由乳腺外科医生投票的科学影响奖。
评论
interesting movement
$Icecure Medical(ICCM.US$
Is this just me? Or is it quite odd the price keeps dropping despite the good news?
Not neccessarily dropping but it keeps going up and down.
Shorts sellers trying to bury the stock? I’m not sure! Anyone able to answer my question?
Is this just me? Or is it quite odd the price keeps dropping despite the good news?
Not neccessarily dropping but it keeps going up and down.Shorts sellers trying to bury the stock? I’m not sure! Anyone able to answer my question?
$Icecure Medical(ICCM.US$ buy the dip!!
2
$Icecure Medical(ICCM.US$ why drop?
Medical Device Company Seeks FDA Approval For Promising Breast Cancer Treatment
IceCure Medical's Breakthrough in Breast Cancer Treatment: A Beacon of Hope.
In an era where the fight against breast cancer sees continuous battles, a significant development emerges from IceCure Medical Ltd., promising a new dawn in the treatment of early-stage breast cancer. The company recently announced the final results of its ICE3 trial, which could potentially revolutionize how we approach breast cancer treatm...
In an era where the fight against breast cancer sees continuous battles, a significant development emerges from IceCure Medical Ltd., promising a new dawn in the treatment of early-stage breast cancer. The company recently announced the final results of its ICE3 trial, which could potentially revolutionize how we approach breast cancer treatm...
$Icecure Medical(ICCM.US$ 96.3% Recurrence free rate is a feat for this breast cancer treatment. Yet again, people didnt really put notice on this even if 30% of all diagnosed cancers in women is breast cancer.
4
阅读更多
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅